Natalia Buenache

Mrs. Natalia Buenache

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JRJuan Manuel Rosa-Rosa
Juan Manuel Rosa-Rosa
ICIsabel Cuenca
Isabel Cuenca
AMAlejandro Medina-Herrera
Alejandro Medina-Herrera
IVIria Vazquez
Iria Vazquez
ASAndrea Sánchez-Delacruz
Andrea Sánchez-Delacruz
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
Next-generation sequencing (NGS) has greatly improved our ability to detect the genomic aberrations occurring in multiple myeloma (MM); however, its transfer to routine clinical labs and its validation in clinical trials remains to be established. We designed a capture-based NGS targeted panel to identify, in a single assay, known genetic alterations for the prognostic stratification of MM. The NGS panel was designed for the simultaneous study of single nucleotide and copy number variations, insertions and deletions, chromosomal translocations and V(D)J rearrangements. The panel was validated using a cohort of 149 MM patients enrolled in the GEM2012MENOS65 clinical trial. The results showed great global accuracy, with positive and negative predictive values close to 90% when compared with available data from fluorescence in situ hybridization and whole-exome sequencing. While the treatments used in the clinical trial showed high efficacy, patients defined as high-risk by the panel had shorter progression-free survival (p = 0.0015). As expected, the mutational status of TP53 was significant in predicting patient outcomes (p = 0.021). The NGS panel also efficiently detected clonal IGH rearrangements in 81% of patients. In conclusion, molecular karyotyping using a targeted NGS panel can identify relevant prognostic chromosomal abnormalities and translocations for the clinical management of MM patients.

18 June 2026 in HemaSphere
Verified
Journal Article
Open access
NBNatalia Buenache
Natalia Buenache
MLMarta Lasa
Marta Lasa
AAAndrés Arroyo
Andrés Arroyo
CGCarmen González
Carmen González
LHLarissa Haertle
Larissa Haertle
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
Measurable residual disease assessment in bone marrow (BM‐MRD) is a crucial prognostic factor in multiple myeloma (MM), but its clinical use has some caveats, such as invasiveness, poor spatial representativity, and serial sampling. Novel minimally invasive approaches for monitoring peripheral residual disease (PRD) could facilitate its clinical use. We aimed to investigate a sensitive method for detecting PRD in patients with MM. This study included 84 patients enrolled in PETHEMA/GEM clinical trials, and a total of 292 longitudinal samples were analyzed. BM‐MRD in these patients was assessed using EuroFlow‐based next‐generation flow cytometry (NGF) and PRD was simultaneously examined in cell‐free DNA (cfDNA) using AltumTrackSeq®, a highly sensitive next‐generation sequencing (NGS) method based on patient‐specific multiplexed amplicon mini‐panels that target somatic mutations identified at diagnosis. Our findings revealed that automated isolation methods enabled standardization and yielded cfDNA levels comparable to manual protocols. A high median cfDNA concentration of 393.2 ng was obtained, with a range from 17.3 to 6300 ng. Furthermore, we demonstrated that compared with traditional BM‐MRD by NGF, our ctDNA‐NGS approach showed a higher positive predictive value (PPV, 88.9% vs. 34.5%) and specificity (Sp, 98.4% vs. 70.3%) for predicting relapse during the follow‐up period. Detectable ctDNA was associated with a high risk of progression and/or death (HR, 11.5; 95% CI, 2.66–49.4), and this was confirmed in the multivariate analysis. In conclusion, this assay offers a method for detecting imminent relapse risk in the peripheral blood of MM patients.

25 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NBNatalia Buenache
Natalia Buenache
ASAndrea Sánchez-Delacruz
Andrea Sánchez-Delacruz
ICIsabel Cuenca
Isabel Cuenca
AGAlicia Giménez
Alicia Giménez
LMLaura Moreno
Laura Moreno
JRJuan Manuel Rosa-Rosa
Juan Manuel Rosa-Rosa
Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of pathogenic CD138+ plasma cells (PPCs) in bone marrow (BM). Recent years have seen a significant increase in the treatment options for MM; however, most patients who achieve complete the response ultimately relapse. The earlier detection of tumor-related clonal DNA would thus be very beneficial for patients with MM and would enable timely therapeutic interventions to improve outcomes. Liquid biopsy of “cell-free DNA” (cfDNA) as a minimally invasive approach might be more effective than BM aspiration not only for the diagnosis but also for the detection of early recurrence. Most studies thus far have addressed the comparative quantification of patient-specific biomarkers in cfDNA with PPCs and BM samples, which have shown good correlations. However, there are limitations to this approach, such as the difficulty in obtaining enough circulating free tumor DNA to achieve sufficient sensitivity for the assessment of minimal residual disease. Herein, we summarize current data on methodologies to characterize MM, and we present evidence that targeted capture hybridization DNA sequencing (tchDNA-Seq) can provide robust biomarkers in cfDNA, including immunoglobulin (IG) rearrangements. We also show that detection can be improved by prior purification of the cfDNA. Overall, liquid biopsies of cfDNA to monitor IG rearrangements have the potential to provide important diagnostic, prognostic, and predictive information in patients with MM.